Sheldon H. Preskorn, MD

Put treatment resistance in perspective with Sheldon H. Preskorn, MD.

Whether an effect is adverse or desired can be a function of the clinical situation.

Drug-drug interactions are complicating COVID-19 treatment. Read what you need to know to keep yourself and your patients safe before and during COVID infection.

New data and an intriguing case example suggest the mortality rate may be decreasing. What does this mean for the days ahead?

This video presents Information that may help you and your patients deal with the pandemic.

Guidance for mental health care practitioners to better explain the complexities of the current crisis to their patients.

What is the nature of the virus turning the world upside down? Dr Sheldon Preskorn shares critical clinical information to better understand the virus, testing, and what might the future hold as we look to turn the corner in this pandemic.

What’s the best way to avoid the paresthesias that can occur in some patients who discontinue SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy?

The modern era of psychopharmacology is only 60 years old, having begun with the discovery of the psychotherapeutic benefits of reserpine, lithium, monoamine oxidase inhibitors, and chlorpromazine in the late 1940s and early 1950s, which was followed a few years later by the synthesis and testing of the tricyclic antidepressants and benzodiazepines.

Over the past 50 years, psychiatry has increasingly become psychiatric medicine coincident with the enormous developments in our understanding of and ability to effectively use clinical psychopharmacology to treat patients with psychiatric illnesses. There have been both increased understanding of the molecular mechanisms underlying the effects of psychiatric medications and increased numbers of psychiatric medications. The latter has occurred in tandem with a similar explosion in the availability of medications to treat a host of other medical conditions. In fact, the repertoire of available medications expands virtually every few weeks.

The incidence of polypharmacy is on the rise, and with the increase comes a greater risk of drug-drug reactions. One survey estimated that patients seeing a psychiatrist may be six times more likely to receive multiple psychotropic medicines compared to patients seen by a primary care physician. This article provides an overview of the extent of polypharmacy, the factors driving the phenomenon and issues clinicians should consider when treating patients who are already taking medicines for other illnesses.